President Donald Trump announced that the United States will impose a 100% tariff on generic drugs imported from India and other countries, starting on August 1, 2028. The announcement was made early in the morning, catching many investors off guard. The move is part of a broader strategy to protect domestic manufacturing.
The Nifty Pharma index fell by 1.6% by noon, reflecting the market’s immediate reaction to the tariff news. Investors are cautious because the tariffs are announced, not yet enforced, and will take effect several years from now. The two‑year tariff‑free window until July 31, 2028, may provide some relief.
The tariffs will rise to 200% on August 1, 2029, after the initial 100% rate. Indian companies will need to decide whether to shift production to the United States to avoid the duty. The decision will depend on cost, logistics, and regulatory hurdles.
Indian pharma firms are already evaluating the impact on their supply chains. Some may look for alternative markets or negotiate with U.S. buyers. Others may lobby for a trade agreement that offers better terms.
This tariff announcement follows a series of U.S. actions on other goods. For example, the U.S. imposed 50% duties on Canadian products and 25% on Brazilian goods. These moves were framed as protection of domestic industries.
A separate U.S. probe on forced labour practices covers about 60 countries, including India, and could add 10–12.5% tariffs to those affected. Another probe on excess manufacturing capacity also lists India as a potential target.
The U.S. and India are currently negotiating a bilateral trade treaty. A favourable agreement could ease tariff pressures and open new export opportunities for Indian companies. The talks are still in progress and no final deal has been announced.
While the tariff news is unsettling, Indian firms have previously adapted to similar shocks by diversifying markets. The long‑term outcome will depend on how quickly the U.S. implements the tariffs and how Indian companies respond.
In the meantime, investors are monitoring the situation closely. The market’s reaction shows that while the immediate impact is limited, the uncertainty remains high until the tariffs are actually enforced.